|

Is Your Life Sciences Company Ready for
Financing?
By David
Lin and Jodi Hansell
[March 2003]
For venture capitalists, Life Science companies have become all
the rage. In 2002, even amidst the continual economic downturn,
investments in the Life Science industry grew significantly as a
percentage of total venture capital investments. Last year, the
Life Sciences sector was notably one of the few fund-raising bright
spots. This bulletin examines the strength of the Life Science industry
relative to the current climate of venture capital investing and
provides an overview of basic issues for a Life Science company
to consider before seeking venture financing.
What is the current state of venture capital investing?
Overall, venture capital financing in 2002 remained weak, following
its steady decline since reaching record-setting levels in 2000,
as shown in the chart below produced by Venture Economics.

Source: Venture Economics
Despite low overall commitment levels from venture capitalists
in 2002, investments in Life Science companies as a percentage of
overall venture capital investments remained resilient and grew
steadily. According to the PricewaterhouseCoopers Money Tree Survey,
last year, the Life Science sector (Biotechnology and Medical Devices
combined) captured $4.7 billion and claimed 22 percent of all venture
capital invested, the highest proportion of total venture capital
in seven years. The attraction toward Life Science Companies continues
to grow, despite the fact that the markets have not rebounded from
recent events.
The 2002 breakdown of investments per industry sector is as follows:
Amount Invested
($) |
2002 Total |
| Industry |
|
| Biotechnology |
$ 2,798,269,600 |
| Business Products and Services |
$ 615,119,000 |
| Computers and Peripherals |
$ 783,054,400 |
| Consumer Products and Services |
$ 283,512,900 |
| Electronics/Instrumentation |
$ 252,800,000 |
| Financial Services |
$ 626,329,200 |
| Healthcare Services |
$ 393,739,200 |
| Industrial/Energy |
$ 804,108,700 |
| IT Services |
$ 1,162,421,800 |
Media and Entertainment |
$ 775,367,200 |
| Medical Devices and Equipment |
$ 1,862,240,500 |
| Networking and Equipment |
$ 2,232,221,000 |
| Other |
$ 28,130,000 |
| Retailing/Distribution |
$ 186,768,100 |
| Semiconductors |
$ 1,178,227,400 |
| Software |
$ 4,318,503,500 |
| Telecommunications |
$ 2,878,197,900 |
| Grand Total |
$ 21,179,010,400 |
Source: PricewaterhouseCoopers Money Tree Survey
Life Sciences investments, broken down by industry
Amount Invested
($M) |
2002
|
| |
1Q |
2Q |
3Q |
4Q |
Total |
| Biopharmaceuticals |
$741.59 |
$1,026.06 |
$521.68 |
$500.72 |
$2,790.05 |
| Healthcare Services |
$41.09 |
$87.20 |
$136.70 |
$100.18 |
$365.17 |
| Medical Devices |
$369.08 |
$519.36 |
$283.88 |
$357.81 |
$1,530.12 |
| Medical Information Systems |
$117.69 |
$247.52 |
$44.80 |
$69.93 |
$479.94 |
| Total |
$1,269.44 |
$1,880.15 |
$987.06 |
$1,028.64 |
$5,165.29 |
Source: VentureOne
The Life Sciences sector had a very prominent showing in the
2002 venture-backed IPO market as well. As the following chart
indicates, two of the top four industries (in terms of number
of IPO's) were in the Life Sciences sector (Medical Device/Equipment
and Biotechnology).
|
2002 Venture-Backed IPOs By Industry
|
| Industry |
Number of
U.S. Venture-Backed IPOs
|
Venture-Backed
Offer Size ($Mill)
|
Venture-Backed
Post Offer
Size
($Mill)
|
Avg.Venture-Backed Offer Value ($Mill)
|
Avg.
Venture-
Backed Post Offer Value ($Mill)
|
| Software |
5 |
217.8 |
940.9 |
43.6 |
188.2 |
| Medical Device/Equipment |
4 |
329.9 |
1461.3 |
82.5 |
365.3 |
| Healthcare Services |
3 |
355.7 |
1362.8 |
118.6 |
454.3 |
| Biotechnology |
2 |
130.5 |
584.0 |
65.3 |
65.3 |
| Information Technology |
2 |
306.0 |
677.4 |
153.0 |
338.7 |
| Media/Entertainment |
1 |
82.5 |
309.2 |
82.5 |
309.2 |
Retailing/Distribution |
1 |
87.5 |
135.5 |
87.5 |
135.5 |
| Financial Services |
1 |
70.2 |
777.8 |
70.2 |
777.8 |
| Consumer Products & Services |
1 |
38.9 |
116.0 |
38.9 |
116.0 |
| Other |
2 |
289.5 |
1905.7 |
80.6 |
952.9 |
| Total |
22 |
1908.5 |
8219.6 |
86.8 |
373.6 |
Source: Thomson Venture Economics &
National Venture Capital Association
What can I do to get my Life Science company ready for VC financing?
To get the attention of investors, it is extremely important that
you put your best foot forward. You will almost always only get
one shot with a venture capitalist, and seldom are there second
chances to make a good first impression. Venture capitalists expect
entrepreneurs to have the basics covered before they meet
with VC's. Although by no means complete, the following list provides
a few ideas to start thinking about when forming your company and
preparing to look for financing.
1. Hire legal counsel and an accountant with industry
knowledge.
You need to retain the services of a lawyer and an accountant knowledgeable
about new technology businesses and, specifically, the Life Sciences
industry. Numerous key decisions unique to Life Science companies
must be made both before and shortly after a Life Science company
is formed. Investors expect new companies to retain competent, experienced
counsel with industry knowledge. Trying to cut costs by avoiding
getting sound, immediate professional advice does not pay off long-term.
2. Give careful consideration to your choice of entity.
It is imperative that your choice of business entity suits your
company's business needs. The choice of Subchapter S corporations,
Subchapter C corporations, limited liability companies and partnerships
all have different consequences for your business.
Eye-opening example:
A company was formed as a limited liability company and received
millions of dollars in investments. Just before its initial public
offering, the company discovered that as a limited liability company,
it could not go public and that it needed to convert to a corporation.
The conversion alone cost over $25,000 and took several weeks. The
conversion process also revealed that earlier decisions made by
the company, not anticipating its conversion into a corporation,
caused it to incur huge tax liabilities. Over the course of several
months, the company's problems were resolved. By that time, however,
the markets had changed, rendering its initial public offering unsuccessful.
3. Protect your intellectual property immediately (ALL of it - not
just patents).
In the Life Science industry, it is essential to get an early start
in securing IP rights to protect innovations and to limit effective
competition. In addition to filing patent applications, it is critical
that all persons who come into contact with your copyrights, trademarks
and trade secrets sign appropriate agreements. These can be in the
form of non-disclosure, confidentiality and proprietary rights agreements.
Eye-opening example:
A software company hired independent contractors to add art and
graphics to its software product and to assist with writing the
business plan. Before the product hit the market, the independent
contractors claimed they had rights to the technology and should
be allocated part of the profits. Since the Company did not have
the time or capital to dispute the claims, and there was no agreement
in place to protect the Company, the management decided to allocate
some of the profits to the independent contractors rather than entering
into litigation or a lengthy dispute. Essentially, they gave away
their own profits because they did not take the right steps to protect
themselves in the first place.
4. Choose strong management.
Industry analysts have noted that venture capitalists invest in
management teams, not just technology. In fact, for many VCs, management
is the number one issue when considering an investment. If you are
not able to afford full-time management, you should consider assembling
a high level board of advisors that believe in your business, are
willing to support and promote your business and who are willing
to accept equity in lieu of cash.
5. Write an Intelligent Business Plan.
Venture capitalists expect to see that entrepreneurs have thoroughly
thought out the details of their business plan. One section often
overlooked is the section on competition. Although no one may have
a product identical to yours, it is critical that you define your
space as closely and accurately as possible. You should describe
the related markets generally and name several specific companies.
You should distinguish yourself from your competition in an intelligent
manner, but you must show investors that you know what you are up
against.
A more detailed description of the elements of a business plan
can be founded in the publication Cracking
the New E-conomy, published by the Washington Software Alliance
in cooperation with Davis Wright Tremaine and other partners. A
copy of the book may be purchased from DWT's
online Bookstore.
6. Develop a Product Prototype.
It is important that you have a demonstrable product before you
go in front investors. Nothing captures the hearts and minds of
investors better than seeing how a product will be built and how
it will work upon completion. Help them picture what they are buying
and help them picture the end product. In addition, a well thought
out sales and marketing plan is essential which gives a clear understanding
of initial market focus and potential diversity of technology applications.
For further guidance or to seek specific information, please contact
DWT's Life Science attorneys. With offices from coast to coast,
DWT Life Science attorneys combine their experience in diverse practice
areas with industry knowledge to help you reach your business goals.
FOR FURTHER INFORMATION, PLEASE CONTACT THE AUTHORS:
Jodi Hansell, 212-603-6416,
jodihansell@dwt.com
David Lin, 206-903-3963,
davidlin@dwt.com
This Life Sciences Advisory Bulletin
is a publication of the Life Sciences Group of Davis Wright Tremaine
LLP. Our purpose in publishing this Advisory Bulletin is to inform
our clients and friends of developments in life sciences law. It
is not intended, nor should it be used, as a substitute for specific
legal advice as legal counsel may only be given in response to inquiries
regarding particular situations.
return to Advisory Bulletins
main page
|